

An AACR Special Conference on

## **Tumor Immunology:**

### **Multidisciplinary Science Driving Basic and Clinical Advances**

*Presented in conjunction with the Cancer Immunology Working Group of the AACR*

December 2-5, 2012 • InterContinental Miami Hotel • Miami, FL

## **Sunday, December 2**

**7:00 p.m.-9:00 p.m. Welcoming Remarks and Keynote Talks**  
Trianon

**T cells vs. tumor cells: Arming/deploying T cells for a successful battle**  
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA

**The molecular basis of tumor immunogenicity**  
Robert D. Schreiber, Washington University, St. Louis, MO

**9:00 p.m.-10:30 p.m. Opening Reception**  
Mezzanine East

## **Monday, December 3**

### **BASIC INSIGHTS INTO IMMUNE MECHANISMS PROMOTING CANCER DEVELOPMENT AND PROGRESSION**

**7:00 a.m.-8:00 a.m. Continental Breakfast**  
Mezzanine East

**8:00 a.m.-10:00 a.m. Session 1: Inflammation and Cancer Initiation**  
Trianon

*Chairperson: Drew M. Pardoll, Johns Hopkins University,  
Baltimore, MD*

**Spontaneous and therapy-induced T cell responses to cancer**  
Thomas Blankenstein, Max Delbruck Center for Molecular Medicine, Berlin, Germany

**T cell subsets in the tumor microenvironment**  
Weiping Zou, University of Michigan, Ann Arbor, MI

**Dominant signaling pathways in the immune microenvironment of cancer**  
Drew M. Pardoll

**Oncogenic driver mutations shape the nature of immune responses in tumors\***  
Vladislava Juric, University of California, San Francisco, CA

**Vaccination against microsatellite-unstable colorectal cancer with frameshift peptide antigens\***  
Matthias Kloor, University Hospital Heidelberg, Heidelberg, Germany

- 10:00 a.m.-10:30 a.m.**      **Break**  
Mezzanine East
- 10:00 a.m.-7:30 p.m.**      **Poster Viewing – Session A**  
Mezzanine East  
*Posters to be presented in Poster Session A will be available for viewing throughout the day.*
- 10:30 a.m.-12:30 p.m.**      **Session 2: The Tumor Microenvironment:  
Recent Advances**  
Trianon  
*Chairperson: Lisa M. Coussens, Oregon Health and Science University, Portland, OR*

**Inflammation and cancer: Reprogramming the immune microenvironment as an anticancer therapeutic strategy**

Lisa M. Coussens

**Immune escape mechanisms in lymphoid malignancies**

Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

**Regulation of myeloid-derived suppressor cells in tumor microenvironment**

Dmitry I. Gabrilovich, H. Lee Moffitt Cancer Center, Tampa, FL

**Myofibroblasts activated upon tissue injury and hypoxia promote development of castration-resistant prostate cancer\***

Massimo Ammirante, University of California San Diego, La Jolla, CA

**Restoring T cell immunosurveillance in pancreatic carcinoma using CD40 agonists\***

Gregory L. Beatty, University of Pennsylvania, Philadelphia, PA

- 12:30 p.m.-2:30 p.m.**      **Free Time/Lunch on Own**

\*Short talks from proffered papers

2:30 p.m.-4:30 p.m.

**Session 3: The Tumor Microenvironment:  
Translational Updates**

Trianon

*Chairperson: Glenn Dranoff, Dana-Farber Cancer Institute,  
Boston, MA*

**The interplay of inflammation and cancer**

Glenn Dranoff

**Cancer inflammation in pancreatic carcinoma**

Robert H. Vonderheide, University of Pennsylvania, Philadelphia, PA

**Tipping the balance from a procarcinogenic to anticancer response in pancreatic cancer**

Elizabeth M. Jaffee, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

**Aptamer-targeted delivery of Smad3 or RNF111 siRNAs renders CD8+ T cells resistant to TGF $\beta$  inhibition and potentiates vaccine-induced antitumor immunity\***

Randall Brennenman, Miller School of Medicine, University of Miami, Miami, FL

**Prevention of pancreatic intra-epithelial neoplasm progression by a *Listeria monocytogenes* vaccine targeting mutated Kras, an early genetic event in pancreatic tumor development\***

Bridget Keenan, Johns Hopkins School of Medicine, Baltimore, MD

4:30 p.m.-7:00 p.m.

**Poster Session A/Reception**

Mezzanine East

7:00 p.m.-

**Evening Off/Dinner on Own**

**Tuesday, December 4**

**ENGINEERING ENHANCED IMMUNE RESPONSES TO CANCER**

7:00 a.m.-8:00 a.m.

**Continental Breakfast**

Mezzanine East

7:00 a.m.-5:30 p.m.

**Poster Viewing – Session B**

Mezzanine East

*Posters to be presented in Poster Session B will be available for viewing throughout the day.*

\*Short talks from proffered papers

**8:00 a.m.-10:00 a.m.**

**Session 4: Checkpoint Pathways Regulating Immune Responses to Cancer**

Trianon

*Chairperson: James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX*

**Immune checkpoint blockade in cancer therapy: New insights and opportunities**

James P. Allison

**Antibody blockade of multiple negative T cell regulators contribute to antitumor responses**

Alan J. Korman, Medarex Inc., Milpitas, CA

**Translation of an OX40 agonist: Putting a foot on an immunologic gas pedal**

Andrew D. Weinberg, Earle A. Chiles Institute, Portland, OR

**Identification of novel immune checkpoints and their implementation as mAb targets for cancer immunotherapy\***

Ofer Levy, Compugen Ltd., Tel Aviv, Israel

**Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer\***

Christian Klein, Roche Glycart AG, Schlieren, Switzerland

**10:00 a.m.-10:30 a.m.**

**Break**

Mezzanine East

\*Short talks from proffered papers

10:30 a.m.-12:30 p.m.

**Session 5: Advances in the Development of  
Combinatorial Immune-Based Therapies that  
Target Checkpoint Pathways**

Trianon

*Chairperson: Padmanee Sharma, The University of Texas MD  
Anderson Cancer Center, Houston, TX*

**Phase I trial of targeted therapy with PSA-TRICOM vaccine and ipilimumab in  
patients with metastatic castration-resistant prostate cancer**

James L. Gulley, National Cancer Institute, Bethesda, MD

**Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-  
CTLA-4**

Padmanee Sharma

**Role of PD-1 and LAG-3 in cancer immunotherapy**

Charles G. Drake, Johns Hopkins University, Baltimore, MD

**Granulocyte macrophage colony stimulating factor (GM-CSF) pancreas tumor  
vaccine in combination with blockade of PD-1 in a preclinical model of pancreatic  
cancer\***

Kevin C. Soares, Johns Hopkins Medical School, Baltimore, MD

**Genetic analysis and therapeutic targeting of IDO pathways in cancer\***

George C. Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA

12:30 p.m.-3:00 p.m.

**Poster Session B/Lunch**

Mezzanine East

\*Short talks from proffered papers

3:00 p.m.-5:20 p.m.

**Session 6: Innovations in Adoptive T Cell Therapy**

Trianon

*Chairperson: Carl H. June, University of Pennsylvania, Philadelphia, PA*

**Engineered T cell therapies for cancer**

Carl H. June

**Preclinical models to study tumor-infiltrating chimeric antigen receptor-expressing lymphocyte hypofunction in adoptive T cell therapy (ACT) \***

Edmund Moon, University of Pennsylvania, Philadelphia, PA

**Fibroblast activation protein as a universal target for chimeric antigen receptor T cell therapy in solid tumors\***

Liang-Chuan S. Wang, University of Pennsylvania, Philadelphia, PA

**Merkel cell carcinoma therapy with viral oncoprotein-specific T cells in combination with immunostimulatory adjuvants**

Paul Nghiem, University of Washington, Seattle, WA

**T cell adoptive therapy for cancer: Translating the science**

James C. Yang, National Cancer Institute, Bethesda, MD

**Enhanced in vivo persistence and therapeutic activity of combined transferred polyclonal melanoma-reactive CTL generated in presence of IL-21 and anti-CTLA4\***

Aude G. Chapuis, Fred Hutchinson Cancer Research Center, Seattle, WA

**Early TCR $\alpha$  expression during T cell development for the generation of enhanced-affinity TCRs for TCR gene therapy\***

Thomas M. Schmitt, Fred Hutchinson Cancer Research Center, Seattle, WA

5:20 p.m.-

**Free Time/Dinner on Own**

\*Short talks from proffered papers

## Wednesday, December 5

IMMUNOTHERAPEUTICS: FOCUS ON HUMAN STUDIES

7:00 a.m.-8:00 a.m.

### Continental Breakfast

Mezzanine East

8:00 a.m.-10:00 a.m.

### Session 7: T Cell Precursors, Memory Subsets, and Control of Adoptive Therapy

Trianon

*Chairperson: Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, WA*

#### **Chimeric antigen receptor design and T cell subsets in adoptive therapy**

Stanley Riddell

#### **Sugar high: Glycolytic flux wrecks stem cell-like T cells**

Nicholas P. Restifo, Center for Cancer Research, National Institutes of Health, Bethesda, MD

#### **Using viruses to enhance T cell therapy for cancer**

Cliona M. Rooney, Baylor College of Medicine, Houston, TX

#### **Advanced T cell engineering for cancer immunotherapy**

Michael Jensen, Seattle Children's Hospital, Seattle, WA

10:00 a.m.-10:30 a.m.

### Break

Mezzanine East

\*Short talks from proffered papers

10:30 a.m.-12:30 p.m.

**Session 8: From Regulatory Pathways to Multimodality  
Immunotherapy Approaches: A Translational Paradigm**

Trianon

*Chairperson: Ronald Levy, Stanford University, Stanford, CA*

**Cervical tissue T cells in HPV disease**

Cornelia L. Trimble, Johns Hopkins University, Baltimore, MD

**Endothelial regulation of T cell trafficking in tumors**

George Coukos, University of Pennsylvania, Philadelphia, PA

**Local immunomodulation at a single site of tumor generates a therapeutic immune  
response that cures metastatic disease at distant sites, including the brain**

Ronald Levy

**Autologous whole-tumor antigen combinatorial immunotherapy for recurrent ovarian  
cancer\***

Lana E. Kandalaft, University of Pennsylvania, Philadelphia, PA

**Genetically engineered T cells redirected against cancer-associated fibroblasts to  
potentiate immunotherapeutic effects\***

Sunitha Kakarla, Baylor College of Medicine, Houston, TX

12:30 p.m.-12:45 p.m.

**Closing Remarks/Departure**

Trianon

\*Short talks from proffered papers